DNTP005921
dTTP
| dNTP Pool | |
|---|---|
| Pool identifier | POOL001479 |
| Members of this Pool |
|
Last modified: 10/Sep/2021
| Results | |
|---|---|
| Publication |
Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N, Dianov GL, Verrill C, Macaulay VM, Ying S, La Thangue NB, D'Angiolella V, Ryan AJ, Humphrey TC: Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.,
Cancer Cell, 2015
PubMed PMCID |
| Value | 1 | Dimension | fold change |
| Error | Error not provided. |
| Relative compared to | control |
| Data presentation in publication | diagram |
| Source | |
|---|---|
| Source organism |
human
(Homo sapiens)
Taxonomy 9606 |
| Sample source | cell line |
| Tissue type | human osteosarcoma |
| CLO Cell line name | U-2 OS cell (CLO:0009454) |
| Cell line/type as in publication | U-2 OS |
| Compartment | whole cell |
| Experiment Details | |
|---|---|
| Measurement type | dNTP incorporation assay |
| Extraction method | methanol |
| Remarks to measurement type | Sherman and Fyfe |
| Growth conditions | U2OS cells stably expressing a degradation-resistant mutant RRM2 (T33A), transfected with control siRNA (48 hr) prior to treatment with AZD1775 (200 nM) (24 hr). |
| Treatment | |
|---|---|
| Drug/stress type | stress |
| PubChem | 24856436 |
| Applied drug | AZD1775 |
| Treatment details/effects | transfection and vehicle (DMSO) control; stable expression of degradation-resistant mutant RRM2 (T33A) |
| Genes and Proteins | |
|---|---|
| Gene name | RRM2 |
| Gene identifier | 6241 |
| Protein name | Ribonucleoside-diphosphate reductase subunit M2 |
| Protein identifier | P31350 |
| Genetic manipulation/variation | extrachromosomal expression of mutant protein |
| Mutation in protein | degradation-resistant mutant RRM2 (T33A) |